Visit LathamDrive– A new site with resources to help emerging companies grow.

Christopher D. Hazuka

Silicon Valley | San Diego
  • 140 Scott Drive
  • Menlo Park, CA 94025
  • USA

Dr. Christopher Hazuka advises life sciences companies on the agreements and transactions that are essential to their success at all stages of their life cycle, drawing on his experience as a scientist and former in-house counsel.

Dr. Hazuka, based in both San Diego and Silicon Valley, brings clients a scientist’s sensibility, a passion for creating synergies to bring innovation to market, and a pragmatic understanding of the full complement of business and legal issues clients face. In particular, he helps established and emerging life sciences companies by providing problem-solving advice to structure, negotiate, and execute a myriad of transactions, such as:

  • Complex collaborations
  • Intellectual property and technology licenses
  • Relationships to assist in developing drug candidates and innovative technologies
  • Manufacturing and quality agreements
  • Commercial agreements, including profit sharing and co-promotion agreements
  • University licenses
  • Clinical trial agreements

In the context of strategic transactions, he advises on:

  • Due diligence and disclosure matters
  • Venture financings, public offerings, and M&A transactions

Dr. Hazuka earned a PhD at Stanford University in the Neurosciences Program for his work in Dr. Richard Scheller’s laboratory on the molecular mechanisms of neurotransmission. He later served as in-house counsel for Orexigen Therapeutics, an emerging company that successfully developed and commercialized a drug to treat obesity. At the La Jolla, California-based company, Dr. Hazuka assisted with challenging issues across the company’s full range of legal matters.

He also clerked for Judge Jeremy Fogel of the United States District Court of Northern California, assisting on several high-stakes technology patent litigation matters.

Dr. Hazuka has advised a wide variety of life sciences companies and firms. A representative sampling includes:

Emerging Companies

  • Castle Creek Pharmaceuticals
  • ChemoCentryx
  • Ideaya Biosciences
  • Ignyta
  • Neurelis
  • Phathom Pharmaceuticals
  • Regulus Therapeutics
  • Verge Genomics

Established Companies

  • Allergan
  • Kyowa Hakko Kirin
  • Ligand Pharmaceuticals
  • Terumo

Representative transactions include:

  • Castle Creek’s collaboration with Fibrocell to develop and commercialize a gene therapy
  • License agreements with Recida and Lyzz Capital for development and commercialization in China
  • Licenses in connection with formation of companies by California-based Frazier Healthcare, including Phathom Pharmaceuticals’ license agreement with Takeda
  • Distribution agreements on behalf of Tokyo-based Terumo, including with US-based startup Orchestra Biomed
  • Orexigen’s collaboration with Takeda
  • Vivelix’s collaboration with Idera to commercialize and develop a GI disorder candidate
  • Allergan’s collaborations with Molecular Partners and Serenity
  • CytomX Therapeutics’ collaboration with Astellas Pharma for the discovery, research, development, and commercialization of novel T-cell engaging bispecific antibodies targeting CD3 and selected tumor cell surface antigens for the treatment of cancer, using CytomX’s Probody® therapeutic technology platform
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.